<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02634723</url>
  </required_header>
  <id_info>
    <org_study_id>061501</org_study_id>
    <nct_id>NCT02634723</nct_id>
  </id_info>
  <brief_title>Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A</brief_title>
  <official_title>Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post-marketing safety study is to evaluate the safety, immunogenicity,&#xD;
      and effectiveness of ADVATE in previously untreated patients (PUPs) in China with moderate to&#xD;
      severe hemophilia A.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 23, 2015</start_date>
  <completion_date type="Actual">June 30, 2016</completion_date>
  <primary_completion_date type="Actual">June 30, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of high titer, low titer and transient Factor VIII (FVIII) inhibitors developed</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and type of other serious and non-serious adverse events (AEs)</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
    <description>Other AEs refers to AEs other than Factor VIII (FVIII) inhibitors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and type of bleeding episodes treated with ADVATE</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding episodes treated with 1, 2, 3, â‰¥ 4 infusions of ADVATE</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized bleeding rate (ABR) of participants treated prophylactically and on-demand with ADVATE</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized joint bleeding rate (AJBR) of participants treated prophylactically and on-demand with ADVATE</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of exposure days (EDs) to ADVATE</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total units of ADVATE administered</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of exposure days (EDs) to all Factor VIII (FVIII) products</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total units of all Factor VIII (FVIII) products administered</measure>
    <time_frame>Throughout the study period of 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">21</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Previously Untreated Patients (PUPs)</arm_group_label>
    <description>PUPs in China with Moderate to Severe Hemophilia A</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Octocog alfa (recombinant human coagulation factor VIII)</intervention_name>
    <arm_group_label>Previously Untreated Patients (PUPs)</arm_group_label>
    <other_name>ADVATE</other_name>
    <other_name>Recombinant antihemophilic factor</other_name>
    <other_name>plasma/albumin-free method (rAHF-PFM</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Previously untreated patients (PUPs) in China with moderate to severe hemophilia A.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Previously untreated patient (PUP) in China with moderate to severe hemophilia A.&#xD;
&#xD;
          2. Investigator prescribed ADVATE as the predominant therapeutic agent for the management&#xD;
             of hemophilia A&#xD;
&#xD;
          3. Informed consent form from patient and/or legal representative will need to be signed&#xD;
             per local regulation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of an inherited or acquired hemostatic defect other than hemophilia A, and&#xD;
             any other clinically significant chronic disease&#xD;
&#xD;
          2. Participants who participated in another investigational FVIII drug study, or had&#xD;
             participated in any clinical study involving an investigational FVIII drug during the&#xD;
             course of the observation period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Hematology and Oncology, Harbin The First Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150070</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College of Huazhong University of Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430074</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Children's Hospital Affiliated to Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210019</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Blood Center</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250014</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial Hospital of TCM/The First Affiliated Hospital of Zhejiang Chinese Medical University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/5f6b5fc24db2bf003ab45811</url>
    <description>To obtain more information on the study, click here/on this link.</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2015</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

